CORRECTION – Bringing Advanced Vascular Diagnostics to the Western US with the SmartVascular Dx™ Test
MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now available in the Western United States. This innovative diagnostic tool aims to enhance vascular health monitoring in the region.
We are also pleased to announce that we are now in-network with Blue Cross Blue Shield of Arizona, allowing us to better serve this market. Additionally, we have secured contracts that enable the reimbursement of claims through United Healthcare, Aetna, Cigna, and Humana on a nationwide basis. These claims will be reimbursed on an out-of-network basis and apply to their PPO and Medicare Advantage plans. We are happy to share that the SmartVascular Dx test is also covered by Medicare.
Why SmartVascular Should Be Your Go-To Test
The SmartVascular Dx test is essential for the early detection of vascular disease, which is a significant health concern in many communities. Its capabilities enable timely and targeted interventions that can significantly improve health outcomes.
Furthermore, we would like to remind our partners that we have collaborated with My One Medical Source® (MOMS), and its network of MAPs: Medical Access Points/Providers™, which will facilitate specimen collection opportunities for MorningStar Laboratories' patients across the country. As the 'Connection for the Collection™,' MOMS enhances access to testing by bridging labs like ours with the skilled personnel needed for specimen collection.
For more information and to learn how to integrate the SmartVascular Dx test into your practice, please reach out MorningStar Laboratories at 866.299.8998. Join us in our mission to enhance vascular care and improve the health of our communities.
About MorningStar Laboratories
MorningStar Laboratories ('MSL') is a specialty diagnostics development clinical laboratory company that develops, performs, and distributes unique medical tests combining science, technology, and proprietary analytics which aim to detect high-risk diseases with significant unmet medical needs. MSL's laboratory information systems use data from multiple sources, including proteomics, genetics, metabolic, biochemistry, phenotype, imaging, and a patented algorithm to address the most challenging clinical problems related to endothelial and vascular inflammatory issues. Morningstar Laboratories, a subsidiary of Smart Health Diagnostics Company, is a CLIA-Certified and CAP Accredited laboratory offering comprehensive and customized services in accordance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit MorningStar Laboratories at https://mslinc.com/, Facebook, X (formerly Twitter), and LinkedIn.
About My One Medical Source® (MOMs)
My One Medical Source® (MOMS) is a SaaS platform connecting labs and other clients with the skilled labor required to perform specimen collections. The MAP: Medical Access Point/Provider™ Network is comprised of both brick-and-mortar draw sites as well as mobile phlebotomy options in all 50 states and Puerto Rico, which serve as collection solutions for the Labs/Clients on the MOMS platform. To learn more, visit https://www.myonemedicalsource.com/.
Forward-Looking Statements
Forward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance.
Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law.
Media Contact mjjohnson@mslinc.com 866.299.8998
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
26 minutes ago
- Business Wire
Blue Cross Blue Shield of North Dakota to Join Cambia Health Solutions as Newest Affiliated Single-State Blue Plan
PORTLAND, Ore. & FARGO, N.D.--(BUSINESS WIRE)--Cambia Health Solutions (Cambia) and Blue Cross Blue Shield of North Dakota (BCBSND) today announced a strategic affiliation to better serve members with access to care that's simpler and more affordable — and remains close to home. The affiliation will unify all operations and enable the organizations to share best practices for local plan innovation and services, deliver personalized member experiences and leverage Cambia's robust technology infrastructure. Strategic affiliation to better serve members with access to care that's simpler and more affordable — and remains close to home. Share Established in 1995 by four Blue Cross Blue Shield licensees, Cambia is a nonprofit health solutions company that provides management and shared services for local Blue plans across the Pacific Northwest and Mountain West, all connected by a common focus on delivering more for members. 'Affiliating with Cambia allows us to leap ahead in the capabilities we can bring to the North Dakotans we serve,' said Dan Conrad, president and CEO of BCBSND. 'We both have a deep commitment to a strong local presence today and into the future. Backed by Cambia's national scale and resources, we can offer members and customers more affordable plan solutions and personalized health tools, all while continuing to be supported by local employees who understand their health care needs.' Cambia and BCBSND share a legacy of practical innovation and community commitment. Cambia's mission is to transform health care to work better for real people and be economically sustainable. It is a founding partner and investor in Echo Health Ventures, which seeks to invest in and grow great health care companies. The health solutions company brings experience offering high-quality, cost-effective health care through personalized member tools that make it easier for people to navigate their care. BCBSND contributes deep expertise and market leadership in rural health, Medicare and Medicaid solutions, and provider collaboration. 'Cambia works every day to make health care easier and lives better for our members. For decades we've proven that we can do more when we have partners who share in this work,' said Jared Short, president and CEO of Cambia. 'BCBSND's culture and vision fit perfectly as we work together to innovate and transform health care for the communities we serve.' Members retain their current coverage and will continue to use their BCBSND insurance card just as they do today. BCBSND will continue to offer Medicare Advantage through NextBlue of North Dakota. BCBSND will maintain its local plan name, board of directors, and philanthropic foundation. It will also continue its mutual status, meaning it will remain governed by voting policyholders rather than investors. All BCBSND's reserve funds and foundation resources remain in North Dakota. Cambia will also maintain its foundation, and local health plans will operate in Idaho, Oregon, Utah, and Washington, as they do now. The areas of focus for the affiliation include: Improving the care experience with more personalized and connected solutions for members and providers. The affiliation enables investment in care solutions such as advanced primary care, mobile platforms for on-demand and virtual primary care, expanded tools for maternal and family health, and programs tailored to local communities. The affiliation enables investment in care solutions such as advanced primary care, mobile platforms for on-demand and virtual primary care, expanded tools for maternal and family health, and programs tailored to local communities. Expanding capabilities and tools to meet the unique local health needs of members and communities. Shared technology and data will create new opportunities for plans to collaborate with providers, employers and communities to support care that is more accessible, understandable and actionable for members and providers. Shared technology and data will create new opportunities for plans to collaborate with providers, employers and communities to support care that is more accessible, understandable and actionable for members and providers. Investing in transformative, financially sound solutions to improve members' health outcomes. Combined resources across operations and technology will increase agility, expand plan capabilities, provide cost savings, and simplify the experience for members and customers. The strategic affiliation is subject to regulatory approval in North Dakota and is expected to close in 2026. For more information, visit the fact sheet. About Blue Cross Blue Shield of North Dakota BCBSND was founded in 1940 with the mission to provide members with affordable access to health care across the state. As an independent licensee of the Blue Cross and Blue Shield Association (BCBSA), BCBSND is committed to transforming care and health across the state to improve outcomes, lower cost trends and make it easier to shop, buy and use health care coverage. Members have access to unmatched local service and to a comprehensive network of health care providers across the state, the nation and more than 190 countries. About Cambia Health Solutions Cambia Health Solutions, headquartered in Portland, Oregon, is dedicated to transforming health care. We put people at the heart of everything we do as we work to make the health care system more economically sustainable and efficient for people and their families. Our company reaches millions of Americans nationwide, including more than 3.6 million people served by our regional health plans. To learn more about us, visit
Business Wire
an hour ago
- Business Wire
Keysight Completes Industry-First PSA Certified Level 4 Evaluation for Silicon Labs' SiXG301 SoC
SANTA ROSA, Calif.--(BUSINESS WIRE)-- Keysight Technologies, Inc. (NYSE: KEYS) has completed the industry's first PSA Certified Level 4 security evaluation for Silicon Labs' Series 3 Secure Vault™ on the SixG301 wireless SoC, marking a significant advancement in the security assurance of connected devices. As IoT adoption accelerates across industries, the security threat landscape continues to evolve. Devices are increasingly targeted by sophisticated attackers with advanced tools and techniques. Certification frameworks like PSA Certified are critical in helping manufacturers prove that their devices can withstand these threats. Level 4, the most advanced assurance level in the framework, specifically tests the resilience of core security components such as Root of Trust (RoT), components, and secure elements (SE) embedded within connected platforms. These components are essential to protecting data, firmware, and device functionality throughout the product lifecycle. As an authorized PSA Certified Test Lab, Keysight conducted the Level 4 evaluation through its advanced security lab, employing in-depth design reviews, vulnerability analysis, and sophisticated attack simulations such as Side-Channel Analysis and Fault Injection. These tests validated the product's resilience against sophisticated threats. While the initial plan was to achieve Level 3, Keysight's deep expertise and flexible approach helped Silicon Labs achieve the top-tier Level 4 certification. This certification confirms the device's robustness and Keysight's critical role in helping customers bring secure, trusted technologies to market. Rohit Ravichandran, Product Manager for IoT Security at Silicon Labs, said: 'This certification is a major milestone for Silicon Labs and a testament to the strength of our collaboration with Keysight. Achieving PSA Certified Level 4 required more than just technical readiness—it demanded a testing partner with deep expertise, flexible processes, and a shared commitment to security excellence. Keysight played a critical role not only in guiding us through the evaluation but in pushing the limits of what we could achieve. Their rigorous approach and hands-on support made it possible to reach this advanced level of assurance.' Marc Witteman, Technical Director at Keysight, said: 'This achievement reflects the culmination of our close and long-standing partnership with Silicon Labs' engineering team and highlights the importance of continuous collaboration in bringing trusted technology to the market. Keysight provides more than certification, we equip customers with the tools, expertise, and support to design and deliver secure products efficiently and confidently.' At Keysight (NYSE: KEYS), we inspire and empower innovators to bring world-changing technologies to life. As an S&P 500 company, we're delivering market-leading design, emulation, and test solutions to help engineers develop and deploy faster, with less risk, throughout the entire product life cycle. We're a global innovation partner enabling customers in communications, industrial automation, aerospace and defense, automotive, semiconductor, and general electronics markets to accelerate innovation to connect and secure the world. Learn more at Keysight Newsroom and
Business Wire
an hour ago
- Business Wire
Altasciences Chosen by Steel Therapeutics to Support the Launch of Pivotal Toxicology Study for Fizurex™
LAVAL, Québec--(BUSINESS WIRE)-- Altasciences is pleased to have been chosen by Steel Therapeutics, Inc. ('Steel'), to initiate a pivotal toxicology study for Fizurex™, a novel topical therapy for the treatment of anal fissures. The GLP-compliant study is currently being conducted at Altasciences' preclinical facility in Columbia, MO. It marks a key milestone in Steel's regulatory development, as the company prepares for an Investigational New Drug (IND) application in early 2026. The GLP-compliant study is currently being conducted at Altasciences' preclinical facility in Columbia, MO. It marks a key milestone in Steel's regulatory development, as the company prepares for an Investigational New Drug (IND) application in early 2026. 'We're proud to be supporting Steel Therapeutics at this key stage of their development journey,' said Steve Mason, Co-COO at Altasciences. 'Our teams are aligned in their commitment to accelerate the delivery of patient-centered therapies. The initiation of this study is another example of how early collaboration and scientific rigor can bring important treatments closer to market.' Fizurex™, a patent-pending compounded wipe, has seen widespread use in clinical practice and is now progressing through the formal regulatory pathway to reach broader patient populations under FDA oversight. Steel engaged Altasciences due to their deep expertise in preclinical safety evaluation and proven ability to execute with speed and precision. 'Working with Altasciences allows us to maintain the highest standards of quality as we move Fizurex™ into its next phase of development,' said Matt Stahl, CEO and Founder of Steel Therapeutics. 'This study represents a major step forward for our company and for the patients who stand to benefit from more consistent, scalable access to this treatment.' Altasciences' integrated, collaborative approach to drug development enables companies like Steel to move efficiently from discovery through to clinical trials, all under one organizational umbrella. 'We look forward to continuing our partnership with Steel Therapeutics as they advance their portfolio of innovative, patient-focused therapies,' added Mason. About Altasciences Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences' integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, research support, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit Steel Therapeutics' mission is to improve the lives of patients by scaling access to compounded drugs that have a proven track record of safety and effectiveness. With a team of pharmacist-founders who have built and operated retail compounding programs, Steel is well-positioned to identify both high-impact drug candidates and innovative delivery systems. Steel has selected a novel treatment for anal fissures as its product entry point. The company's Fizurex™ wipe utilizes a combination therapy that is commonly compounded by pharmacists and incorporates it into a single-use wipe. By bringing rigorous safety and efficacy testing, Current Good Manufacturing Practices (CGMP), and a patient-friendly format to this drug combination, Steel believes it can dramatically improve outcomes for patients.
